Zhongjian Kangqiao Pharmaceutical Group Co., Ltd.

Zhongjian Kangqiao Pharmaceutical Group is a Chinese pharmaceutical company specializing in the research, manufacturing, and distribution of treatments for chronic conditions, with a primary focus on cardiovascular and cerebrovascular diseases. Founded in 2015 and headquartered in the Guangzhou International Bio-island, the company is notable for its core commercial asset, Aluminum Magnesium Aspirin Tablets (II), an exclusive generic formulation in China used as an anti-thrombotic therapy. The company operates multiple GMP-certified production facilities and maintains an extensive sales network covering over 3,500 hospitals and 6,500 pharmacies across nearly 30 provinces. Since 2023, Zhongjian Kangqiao has been listed on the National Equities Exchange and Quotations (NEEQ) as it continues to expand its portfolio of essential medicines and medical devices.